These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31166287)

  • 41. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy.
    Kitazawa Y; Smith P; Sasaki N; Kotake S; Bae K; Iwamoto Y
    Eye (Lond); 2011 Sep; 25(9):1161-9. PubMed ID: 21701528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
    Diestelhorst M; Larsson LI;
    Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension.
    Mishra A; Agrawal M; Tripathi A; Bhirud A; Kumar LCR; Vinod K BB
    J Ocul Pharmacol Ther; 2024 May; 40(4):240-245. PubMed ID: 38598266
    [No Abstract]   [Full Text] [Related]  

  • 46. Preservative-Free Bimatoprost 0.01% Ophthalmic Gel for Glaucoma Therapy: A Phase III Randomized Controlled Trial.
    Muñoz-Negrete FJ; Topouzis F; Oddone F; Nisslé S; Rokicki D; Januleviciene I; Harasymowycz P; Stalmans I
    J Glaucoma; 2024 Jun; 33(6):422-430. PubMed ID: 38506750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.
    Goldberg I; Gil Pina R; Lanzagorta-Aresti A; Schiffman RM; Liu C; Bejanian M
    Br J Ophthalmol; 2014 Jul; 98(7):926-31. PubMed ID: 24667994
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
    Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A;
    Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial.
    Higginbotham EJ; Feldman R; Stiles M; Dubiner H;
    Arch Ophthalmol; 2002 Jul; 120(7):915-22. PubMed ID: 12096962
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia.
    Miyake K; Ota I; Ibaraki N; Akura J; Ichihashi S; Shibuya Y; Maekubo K; Miyake S
    Arch Ophthalmol; 2001 Mar; 119(3):387-94. PubMed ID: 11231772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
    Lopes JF; Hubatsch DA; Amaris P
    BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Efficacy of a Latanoprost/Timolol Fixed Combination Versus Latanoprost and Timolol Gel-forming Solution Unfixed Combination on Daytime Intraocular Pressure.
    Özyol E; Özyol P
    J Glaucoma; 2016 Feb; 25(2):135-9. PubMed ID: 25264990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial.
    Shedden A; Adamsons IA; Getson AJ; Laurence JK; Lines CR; Hewitt DJ; Ho TW
    Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1757-64. PubMed ID: 20437244
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial.
    Kim DW; Shin J; Lee CK; Kim M; Lee S; Rho S
    Sci Rep; 2021 Jul; 11(1):14971. PubMed ID: 34294842
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
    J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis.
    Xing Y; Zhu L; Zhang K; Huang S
    PLoS One; 2020; 15(2):e0229682. PubMed ID: 32106236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis.
    Harasymowycz P; Hutnik C; Rouland JF; Negrete FJM; Economou MA; Denis P; Baudouin C
    Adv Ther; 2021 Jun; 38(6):3019-3031. PubMed ID: 33891269
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension.
    Pachimkul P; Yuttitham K; Thoophom P
    J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S81-7. PubMed ID: 21717884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.